Literature DB >> 19689376

Rho kinase (ROCK) inhibitors and their application to inflammatory disorders.

Philip V LoGrasso1, Yangbo Feng.   

Abstract

Inhibitors of Rho kinase (ROCK) have many potential therapeutic applications. The biological focus of this overview will be on the role of ROCK in inflammatory disorders such as multiple sclerosis and asthma. Many ROCK inhibitors have been described in the primary and patent literature, and a diverse range of chemical scaffolds is beginning to emerge. Some of the structural classes that will be highlighted in this review include: isoquinolines, indazoles, amino-furazans, dihydropyrimidines, aminopyrimidines, benzodioxane carboxamides, benzimidazoles, and chroman amides.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19689376     DOI： 10.2174/156802609789044452

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN： 1568-0266            Impact factor:   3.295


  18 in total

Review 1.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

2.  Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors.

Authors:  Rongshi Li; Mathew P Martin; Yan Liu; Binglin Wang; Ronil A Patel; Jin-Yi Zhu; Nan Sun; Roberta Pireddu; Nicholas J Lawrence; Jiannong Li; Eric B Haura; Shen-Shu Sung; Wayne C Guida; Ernst Schonbrunn; Said M Sebti
Journal:  J Med Chem       Date:  2012-02-15       Impact factor: 7.446

3.  Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2).

Authors:  Roberta Pireddu; Kara D Forinash; Nan N Sun; Mathew P Martin; Shen-Shu Sung; Brian Alexander; Jin-Yi Zhu; Wayne C Guida; Ernst Schönbrunn; Saïd M Sebti; Nicholas J Lawrence
Journal:  Medchemcomm       Date:  2012-01-27       Impact factor: 3.597

Review 4.  Novel therapies for coeliac disease.

Authors:  L M Sollid; C Khosla
Journal:  J Intern Med       Date:  2011-06       Impact factor: 8.989

Review 5.  RhoA/Rho-kinase and vascular diseases: what is the link?

Authors:  Kenia Pedrosa Nunes; Christine S Rigsby; R Clinton Webb
Journal:  Cell Mol Life Sci       Date:  2010-07-29       Impact factor: 9.261

6.  Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a.

Authors:  Shuxia Wang; Kangxing Song; Roshni Srivastava; Chao Dong; Gwang-Woong Go; Na Li; Yasuko Iwakiri; Arya Mani
Journal:  FASEB J       Date:  2015-04-27       Impact factor: 5.191

7.  Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype.

Authors:  Sree Rayavarapu; Jack H Van der Meulen; Heather Gordish-Dressman; Eric P Hoffman; Kanneboyina Nagaraju; Susan M Knoblach
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

8.  A small molecule bidentate-binding dual inhibitor probe of the LRRK2 and JNK kinases.

Authors:  Yangbo Feng; Jeremy W Chambers; Sarah Iqbal; Marcel Koenig; HaJeung Park; Lisa Cherry; Pamela Hernandez; Mariana Figuera-Losada; Philip V LoGrasso
Journal:  ACS Chem Biol       Date:  2013-06-10       Impact factor: 5.100

Review 9.  The interplay of canonical and noncanonical Wnt signaling in metabolic syndrome.

Authors:  Maen D Abou Ziki; Arya Mani
Journal:  Nutr Res       Date:  2018-07-04       Impact factor: 3.315

10.  Gene silencing of SOCS3 by siRNA intranasal delivery inhibits asthma phenotype in mice.

Authors:  Ma Paz Zafra; Carla Mazzeo; Cristina Gámez; Ainara Rodriguez Marco; Ana de Zulueta; Veronica Sanz; Izaskun Bilbao; Jesús Ruiz-Cabello; Jose M Zubeldia; Victoria del Pozo
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.